The aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent glioblastoma multiforme (GBM). We identified patients with histologically confirmed glioblastoma and World Health Organization Grade III glioma who were previously treated with temozolomide plus radiotherapy and received 10 mg/kg bevacizumab intravenous infusion every 2 weeks until disease progression for recurrent disease. A total 24 patients included to this study. Twenty-two patients had GBM, and two patients had WHO grade III glioma. No complete response was observed, five patients (20.8 %) had partial response, nine patients (37.5 %) had stable diseases, and ten patients (41.7 %) had progressive diseases. The overall response rate was 20.8 %. The 6-month PFS rate (PFS6) and median PFS were determined as 37.5 % and 4.1 months, respectively. Median OS was 6.4 months. Performance status of 17 (70.8 %) patients was improved following bevacizumab regimen. Univariate analysis showed that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS (p < 0.001) and OS (p < 0.020). Bevacizumab-related adverse effects were observed in 13 (54.1 %) patients. Grade 3-4 toxicity was observed in 4 (16.6 %) patients. Therapy interruptions were experienced in two patients due to adverse effects. Single-agent bevacizumab is an effective and safe treatment alternative in recurrent GBM. IPS following bevacizumab therapy was a significant predictor of both PFS and OS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-014-0460-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Microsatellite instability-high pancreas adenosquamous carcinoma with postoperative liver metastasis recurrence treated with multimodality therapy achieving complete pathological response.
Front Immunol
December 2024
Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Pancreatic adenosquamous carcinoma (PASC) is a rare subtype of pancreatic cancer (PC), with no established consensus on the optimal treatment for postoperative liver metastasis recurrence. We report a case of a 48-year-old male patient who underwent radical surgery and was pathologically diagnosed with microsatellite instability-high (MSI-H) PASC. The patient experienced liver metastasis recurrence following single-agent gemcitabine adjuvant chemotherapy.
View Article and Find Full Text PDFSystemic Therapy Options for Peritoneal Mesothelioma.
J Natl Compr Canc Netw
October 2024
Thoracic Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials conducted among patients with pleural mesothelioma.
View Article and Find Full Text PDFClinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar.
ESMO Open
November 2024
Gastroenterology and Gastrointestinal Oncology Department, Hôpital Européen Georges-Pompidou, University Paris-Cité (Paris Descartes), SIRC CARPEM, Paris, France.
Article Synopsis
- There is no agreed-upon definition of clinically meaningful outcomes in randomized clinical trials (RCTs) for treating refractory metastatic colorectal cancer (mCRC), despite various recommendations since 2014.
- Many recent RCTs for oncology drug approvals fail to meet the recommended benchmarks set by organizations like ASCO and ESMO, highlighting the need for better standards.
- Quality of life (QoL) is increasingly emphasized alongside efficacy and safety in clinical trials, with the SUNLIGHT trial showing that treatment options like FTD/TPI with bevacizumab can achieve clinically meaningful outcomes while preserving QoL.
PD-1 blockade combined with chemotherapy and bevacizumab in DNA mismatch repair-proficient/microsatellite stable colorectal liver metastases.
J Gastrointest Oncol
August 2024
Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Article Synopsis
- - The study investigates the effectiveness and safety of combining anti-PD-1 therapy with chemotherapy and bevacizumab for patients with pMMR/MSS colorectal liver metastases, an area where traditional immunotherapy shows limited success.
- - In a trial with 12 patients, the combination treatment achieved a 100% disease control rate and a 70% objective response rate, with some patients experiencing complete responses in their tumors.
- - Results suggest that this combined treatment approach is safe, with no serious side effects reported, and may significantly improve tumor regression and the likelihood of patients being disease-free post-treatment.
Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer.
Taiwan J Obstet Gynecol
September 2024
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Female Cancer Foundation, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address:
The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey to fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) of the cervix. She received six cycles of perioperative adjuvant therapy, including three cycles of neoadjuvant therapy (NAT) and three cycles of postoperative adjuvant therapy by using combination of dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m+triweekly cisplatin 40 mg/m), immunotherapy (IO, triweekly pembrolizumab 200 mg) and half-dose anti-angiogenic agent (triweekly bevacizumab 7.5 mg/kg) plus interval radical surgery (radical hysterectomy + bilateral salpingo-oophorectomy + bilateral pelvic lymph node dissection + para-aortic lymph node sampling) and following maintenance therapy with monthly 22 cycles of half-dose of IO (pembrolizumab 100 mg) and concomitant 4 cycles of single-agent CT (paclitaxel 175 mg/m) and 18 cycles of half-dose anti-angiogenic agent (bevacizumab 7.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!